EXCLUSIVE LICENSE AGREEMENT. Upon notice received by the Laboratory from the Cooperator that it wishes to exercise the option referred to in paragraph 5.10.1 above, the terms of the exclusive license will be negotiated promptly by the Laboratory and the Cooperator. Any exclusive license will be subject to the reservation by the Government of a non-exclusive, irrevocable, paid-up license to practice or have practiced on its behalf the Subject Invention throughout the world.
EXCLUSIVE LICENSE AGREEMENT. THIS EXCLUSIVE LICENSE AGREEMENT AND THE ATTACHED APPENDICES A, B, AND C (collectively, the “Agreement”) is made and is effective this 1st day of June, (the “Effective Date”), by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation having its corporate offices located at 0000 Xxxxxxxx Xxxxxx, Xxxxxxx, Xxxxxxxxxx 00000-0000, acting through The Office of Intellectual Property and Industry Sponsored Research of the University of California, Los Angeles, located at 00000 Xxxxxxx Xxxxxx, Xxxxx 000, Xxx Xxxxxxx, XX, 00000-0000, and FIBROCELL SCIENCE, INC. (“Licensee”), a Delaware corporation having a principal place of business at 000 Xxxxxxxxx Xxxx., Xxxxx, XX, 00000.Xxxx Agreement refers to The Regents and Licensee collectively as the “Parties” and individually as a “Party.”
EXCLUSIVE LICENSE AGREEMENT. This Agreement refers to the manuscript of the article having the title and the authors as below: Author(s): #1. First name: Last name: #2. First name: Last name: #3. First name: Last name: #4. First name: Last name: #5. First name: Last name: #6. First name: Last name: From which, Corresponding Author: First name: Last name: to be published by ASERS Publishing (hereinafter ‘Licensor’ or ‘Publisher’) in: Journal of Environmental Management and Tourism, ISSN: 2068-7729, Journal DOI: xxxxx://xxx.xxx/10.14505/jemt, website: xxxx://xxxxxxxx.xxxxxxxxxxxxxxx.xx/jemt, e-mail: xxxx@xxxxxxxxxxxxxxx.xx or xxxxx.xxxx@xxxxx.xxx We agree that the ‘Article’ will be made Open Access under the terms of the Creative Commons Attribution License (xxxxx://xxxxxxxxxxxxxxx.xxx/licenses/by/4.0) which permits use, distribution and reproduction in any medium, provided that the ‘Article’ is properly cited. We hereby grant to ASERS Publishing (‘Publisher’) a non-exclusive license under Attribution 4.0 International (CC BY 4.0) to publish and distribute the article(s) referenced above and any supplemental tables, illustrations or other information submitted therewith that are intended for publication as part of the article (the ‘Article’) in all forms and media (whether now known or hereafter developed), throughout the world, in all languages, for the full term of copyright, effective when and if the ‘Article’ is accepted for publication. This license includes the right to provide the ‘Article’ in electronic and online forms and systems. With respect to supplemental data that we wish to make accessible through a link in the ‘Article’, we hereby grant a non-exclusive license under Attribution 4.0 International (CC BY 4.0) for such linking. If we have agreed with the ‘Publisher’ to make available such supplemental data on a site or through a service of ASERS Publishing, we hereby grant a non-exclusive license under Attribution 4.0 International (CC BY 4.0) for such publication, posting and making available, and further permit indexing and archiving. We agree that the ‘Publisher’ is the owner of the ‘Article’ and that ASERS Publishing retains non-exclusive rights in the definitive final version of the ‘Article’ and embodies all value-adding publisher activities including copy-editing, formatting and (if relevant) pagination (‘the Published Article’). This ‘Article’ is distributed under the terms of the license CC-BY 4.0., which lets others distribute, remix, adapt, and build upon this a...
EXCLUSIVE LICENSE AGREEMENT. This Agreement is made effective the 15th day of October, 2007, by and between Marshfield Clinic (hereinafter called “MARSHFIELD CLINIC”), a nonstock, nonprofit Wisconsin corporation, and Osmetech Molecular Diagnostics (hereinafter called “Licensee”), a corporation organized and existing under the laws of Delaware;
EXCLUSIVE LICENSE AGREEMENT. 56 SECTION 5.18. DEVELOPMENTAL PRODUCTS........................................56 SECTION 5.19. NONCOMPETITION AGREEMENTS.....................................57 SECTION 5.20. WAIVER OF RIGHT OF FIRST REFUSAL..............................57 SECTION 5.21. IGF'S CONTINUED ACCESS TO KEY EMPLOYEES.......................58 ARTICLE VI CONDITIONS PRECEDENT TO THE OBLIGATIONS OF THE PURCHASER
EXCLUSIVE LICENSE AGREEMENT. During the period of negotiation of the Exclusive License Agreement neither Xx. Xxxxxxxx nor any member of his team or any person appointed to represent the University on behalf of Xx. Xxxxxxxx or his team shall enter into any arrangements with third parties which may conflict with the Results, the field of research or terms of this Agreement.
EXCLUSIVE LICENSE AGREEMENT. On or before the Closing Date, Sellers and Purchaser shall enter into the License Agreement in substantially the form set forth in Exhibit G.
EXCLUSIVE LICENSE AGREEMENT. Princeton University and Celator Pharmaceuticals
EXCLUSIVE LICENSE AGREEMENT. TABLE OF CONTENTS
EXCLUSIVE LICENSE AGREEMENT. THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 28th day of September, 2007 (the “Effective Date”) by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 00 Xxxxxxxx Xxxxxx, Sudbury, MA 01776 (“Dicerna”) and City of Hope, a California nonprofit public benefit corporation located at 0000 Xxxx Xxxxxx Xxxx, Duarte, California 91010 (“COH”). Dicerna and COH are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
